PMID- 30427250
OWN - NLM
STAT- MEDLINE
DCOM- 20190507
LR  - 20190507
IS  - 1439-7609 (Electronic)
IS  - 1439-7595 (Linking)
VI  - 29
IP  - 2
DP  - 2019 Mar
TI  - IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review.
PG  - 258-267
LID - 10.1080/14397595.2018.1546357 [doi]
AB  - Tocilizumab (TCZ) is an interleukin-6 (IL-6) inhibitor used for the treatment of 
      rheumatoid arthritis (RA). It was developed in 2008, and its effectiveness is 
      supported by evidence from all over the world based on its first decade of use. 
      Although the overall efficacy and safety profiles of TCZ are similar to those of 
      tumor necrosis factor (TNF) inhibitors, TCZ displays certain differences. The 
      most notable advantage of TCZ is its usefulness as a monotherapy. Additionally, 
      TCZ is favorable in the improvement of systemic inflammatory symptoms such as 
      anemia and fatigue. The low immunogenicity of TCZ contributes favorably to 
      long-term drug retention. Due to frequent relapse after TCZ cessation, TCZ use 
      should be tapered beyond remission. During TCZ therapy, C-reactive protein (CRP) 
      is unable to recognize disease activity and the severity of infection. The most 
      common adverse events (AEs) are infection and abnormalities in laboratory 
      findings including dyslipidemia, neutropenia, thrombocytopenia, and abnormality 
      of liver enzymes. TCZ obscures the symptoms of infection. Therefore, stealth 
      infections without obvious CRP elevation can sometimes cause severe damage to 
      patients. Lower intestinal perforation is an uncommon but serious AE in TCZ 
      therapy. Further clinical investigations will continue to refine the IL-6 
      inhibitory strategy.
FAU - Ogata, Atsushi
AU  - Ogata A
AUID- ORCID: 0000-0003-3944-3442
AD  - a Division of Rheumatology, Department of Internal Medicine, NTT West Osaka 
      Hospital, Osaka, Japan.
AD  - b Department of Respiratory Medicine and Clinical Immunology, Graduate School of 
      Medicine , Osaka University , Osaka , Japan.
FAU - Kato, Yasuhiro
AU  - Kato Y
AUID- ORCID: 0000-0002-4050-2350
AD  - a Division of Rheumatology, Department of Internal Medicine, NTT West Osaka 
      Hospital, Osaka, Japan.
AD  - b Department of Respiratory Medicine and Clinical Immunology, Graduate School of 
      Medicine , Osaka University , Osaka , Japan.
FAU - Higa, Shinji
AU  - Higa S
AD  - a Division of Rheumatology, Department of Internal Medicine, NTT West Osaka 
      Hospital, Osaka, Japan.
FAU - Yoshizaki, Kazuyuki
AU  - Yoshizaki K
AD  - c Graduate School of Information Science and Technology , Osaka University , 
      Osaka , Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190103
PL  - England
TA  - Mod Rheumatol
JT  - Modern rheumatology
JID - 100959226
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Interleukin-6)
RN  - I031V2H011 (tocilizumab)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized/adverse effects/immunology/*therapeutic use
MH  - Antirheumatic Agents/adverse effects/immunology/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Humans
MH  - Interleukin-6/*antagonists & inhibitors/immunology
OTO - NOTNLM
OT  - Interleukin-6
OT  - rheumatoid arthritis
OT  - sarilumab
OT  - sirukmab
OT  - tocilizumab
EDAT- 2018/11/15 06:00
MHDA- 2019/05/08 06:00
CRDT- 2018/11/15 06:00
PHST- 2018/11/15 06:00 [pubmed]
PHST- 2019/05/08 06:00 [medline]
PHST- 2018/11/15 06:00 [entrez]
AID - 10.1080/14397595.2018.1546357 [doi]
PST - ppublish
SO  - Mod Rheumatol. 2019 Mar;29(2):258-267. doi: 10.1080/14397595.2018.1546357. Epub 
      2019 Jan 3.